CD163 and metastatic malignant neoplasm in the lymph nodes: The adverse prognostic impact of stromal CD163+ TAMs remained significant (RFS: P = 0.02, Wald test; Table 1) in a multivariate model when correcting for lymph node metastasis, a known clinical prognostic factor in VSCC (8).